Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
100 Clinical Results associated with Shanghai Dingyue Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shanghai Dingyue Biotechnology Co., Ltd.
100 Deals associated with Shanghai Dingyue Biotechnology Co., Ltd.
100 Translational Medicine associated with Shanghai Dingyue Biotechnology Co., Ltd.